A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

Abstract Background Azithromycin is an orally active synthetic macrolide antibiotic with a wide range of anti-bacterial, anti-inflammatory and antiviral properties. It is a safe, inexpensive, generic licenced drug available worldwide and manufactured to scale and is a potential candidate therapy for...

Full description

Bibliographic Details
Main Authors: Timothy S. C. Hinks, Vicki S. Barber, Joanna Black, Susan J. Dutton, Maisha Jabeen, James Melhorn, Najib M Rahman, Duncan Richards, Daniel Lasserson, Ian D. Pavord, Mona Bafadhel
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Trials
Subjects:
COVID-19
Coronavirus
SAR-CoV-2
Azithromycin
Macrolide
Randomised controlled trial
Online Access:http://link.springer.com/article/10.1186/s13063-020-04593-8

Internet

http://link.springer.com/article/10.1186/s13063-020-04593-8

Similar Items